Cardiology Unit, Ospedale Policlinico San Martino IRCCS, Genoa, Italy.
Department of Internal Medicine, University of Genova, Genoa, Italy.
ESC Heart Fail. 2023 Oct;10(5):3019-3027. doi: 10.1002/ehf2.14459. Epub 2023 Aug 7.
This study aimed to determine whether any change occurred over time in level of evidence (LoE) of therapeutic interventions supporting heart failure (HF) and other European Society of Cardiology guideline recommendations.
We selected topics with at least three documents released between 2008 and April 2022. Classes of recommendations (CoR) and supporting LoE related to therapeutic interventions within each document were collected and compared over time. A total of 1822 recommendations from 18 documents on 6 topics [median number per document = 112, 867 (48%) CoR I] were included in the analysis. There was a trend towards a reduction over time in the percentage of CoR I in HF (46-36-34%), non-ST elevation myocardial infarction (NSTEMI; 78-58-54%), and pulmonary embolism (PE; 65-50-39%) guidelines, with a decrease in the total number of recommendations for HF only. Percentage of CoR I was stable over time around 40% for valvular heart disease (VHD) and atrial fibrillation (AF), and around 60% for cardiovascular prevention (CVP), with an increase in the total number of recommendations for VHD and CVP and a decrease for AF. Among CoR I, 319 (37%) were supported by LoE A, with a decrease over time for HF (56-46-42%), an increase for NSTEMI (29-38-48%) and AF (28-31-36%), a bimodal distribution for PE and CVP, and a lack for VHD.
LoE supporting therapeutic recommendations in contemporary European guidelines is generally low. Physicians should be aware of these limitations, and scientific societies promote a greater understanding of their significance and drive future research directions.
本研究旨在确定支持心力衰竭(HF)和欧洲心脏病学会(ESC)其他指南建议的治疗干预措施的证据水平(LoE)是否随时间发生变化。
我们选择了至少有三篇文献在 2008 年至 2022 年 4 月期间发布的主题。收集并比较了每个文件中与治疗干预相关的建议类别(CoR)和支持的 LoE。共纳入 18 份文件中关于 6 个主题的 1822 条建议(中位数/篇为 112 条,867 条(48%)为 I 类 CoR)。HF(46-36-34%)、非 ST 段抬高型心肌梗死(NSTEMI;78-58-54%)和肺栓塞(PE;65-50-39%)指南中 I 类 CoR 的比例随时间呈下降趋势,HF 指南中建议总数减少。瓣膜性心脏病(VHD)和心房颤动(AF)的 I 类 CoR 比例稳定在 40%左右,心血管预防(CVP)的 I 类 CoR 比例稳定在 60%左右,VHD 和 CVP 的建议总数增加,AF 的建议总数减少。在 I 类 CoR 中,有 319 条(37%)得到 LoE A 的支持,HF 的 LoE A 随时间减少(56-46-42%),NSTEMI 和 AF 的 LoE A 增加(29-38-48%),PE 和 CVP 的 LoE A 呈双峰分布,VHD 缺乏 LoE A。
当代欧洲指南中支持治疗建议的 LoE 普遍较低。医生应该意识到这些局限性,而科学协会则应促进对其意义的更深入理解,并推动未来的研究方向。